BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29741421)

  • 21. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
    Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L
    J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of autologous stem cell transplantation in primary central nervous system lymphoma.
    Ferreri AJ; Illerhaus G
    Blood; 2016 Mar; 127(13):1642-9. PubMed ID: 26834241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central Nervous System Lymphoma.
    Chukwueke UN; Nayak L
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):597-611. PubMed ID: 31229157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy.
    Ferreri AJ; Verona C; Politi LS; Chiara A; Perna L; Villa E; Reni M
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):169-75. PubMed ID: 20584577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
    Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
    Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
    Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
    J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
    Colombat P; Lemevel A; Bertrand P; Delwail V; Rachieru P; Brion A; Berthou C; Bay JO; Delepine R; Desablens B; Camilleri-Broët S; Linassier C; Lamy T
    Bone Marrow Transplant; 2006 Sep; 38(6):417-20. PubMed ID: 16951691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
    Chen T; Liu Y; Wang Y; Chang Q; Wu J; Wang Z; Geng D; Yu JT; Li Y; Li XQ; Chen H; Zhuang D; Li J; Wang B; Jiang T; Lyu L; Song Y; Qiu X; Li W; Lin S; Zhang X; Lu D; Lei J; Chen Y; Mao Y
    J Hematol Oncol; 2022 Sep; 15(1):136. PubMed ID: 36176002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and treatment of primary central nervous system lymphoma with the primary lesion in the hypothalamus: a case report.
    Takao K; Tani A; Suwa T; Kuwabara-Ohmura Y; Nonomura K; Liu Y; Kato T; Mizuno M; Hirota T; Enya M; Iizuka K; Horikawa Y; Saigo C; Kito Y; Miyazaki T; Ohe N; Iwama T; Yabe D
    BMC Endocr Disord; 2021 Jan; 21(1):13. PubMed ID: 33430828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).
    Liu Y; Yao Q; Zhang F
    Int J Oncol; 2021 Mar; 58(3):371-387. PubMed ID: 33650642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
    Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
    Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma.
    Terziev D; Hutter B; Klink B; Stenzinger A; Stögbauer F; Glimm H; Fröhling S; Wickenhauser C; Jordan K; Hurtz HJ; Müller LP; Rüssel J; Weber T
    Eur J Haematol; 2018 Jul; 101(1):115-118. PubMed ID: 29624748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.
    Cheah CY; Joske D; Cull G; Gilbertson M; Opat SS; Tam CS; Wirth A; Seymour JF
    Br J Haematol; 2017 Sep; 178(6):991-994. PubMed ID: 27470657
    [No Abstract]   [Full Text] [Related]  

  • 36. Primary central nervous system lymphoma: Novel precision therapies.
    Mondello P; Mian M; Bertoni F
    Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
    Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
    Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
    Jang JE; Kim YR; Kim SJ; Cho H; Chung H; Lee JY; Park H; Kim Y; Cheong JW; Min YH; Kim JS
    Eur J Cancer; 2016 Apr; 57():127-35. PubMed ID: 26918738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
    Kasamon YL; Jones RJ; Piantadosi S; Ambinder RF; Abrams RA; Borowitz MJ; Morrison C; Smith BD; Flinn IW
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):93-100. PubMed ID: 15682069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.
    Atilla PA; Atilla E; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Demirer T; Ilhan O; Arslan O; Gurman G; Ozcan M
    Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):13-17. PubMed ID: 28633037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.